**Chapter 6**

*Mesothelioma*

immunecorrelates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. 2012;**366**(26):2443-2454

[153] Levallet G, Vaisse-Lesteven M, Le Stang N, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: A series of 157 cases from the MESOPATH group. Journal of Thoracic Oncology. 2012;**7**(3):599-606

[154] Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase

complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/ carboplatin. Clinical Cancer Research.

[155] Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical

and excision repair cross-

2011;**17**(8):2581-2590

Pathology. 2013;**66**:854-861

[156] Zhou J, Zhong H, Zhang J,

Jin S, Roudi R, Ma H. Development and validation of a prognostic signature for malignant pleural mesothelioma. Frontiers in Oncology. 2019;**9**:6-9

[152] Valmary-Degano S, Colpart P, Villeneuve L, et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. European Journal of Surgical Oncology. 2017;**43**(10):1915-1923

**78**
